首页 | 本学科首页   官方微博 | 高级检索  
检索        


Amifostine is a Potent Radioprotector of Salivary Glands in Radioiodine Therapy
Authors:Email author" target="_blank">Hannes?KuttaEmail author  Uwe?Kampen  Christoph?Sagowski  Winfried?Brenner  Karl-Heinz?Bohuslavizki  Friedrich?Paulsen
Institution:Department of Anatomy, Christian Albrecht University of Kiel, Germany. hanneskutta@gmx.de
Abstract:BACKGROUND AND PURPOSE: Salivary gland impairment following high-dose radioiodine treatment is well recognized. Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. This study investigates the radioprotective effects of amifostine in salivary glands of rabbits receiving high-dose radioiodine therapy so as to obtain deeper insight in changes on the cellular and ultrastructural level. MATERIAL AND METHODS: A total of 20 rabbits were investigated. High-dose radioiodine therapy applying 1 GBq (131)I was performed in 16 animals. Eight of these 16 animals received 200 mg/m(2) body surface amifostine prior to high-dose radioiodine therapy. Four additional rabbits served as controls, two receiving amifostine, the other two no treatment at all. Subsequently, salivary glands (submandibular and parotid glands, respectively) of all animals were examined by light and transmission electron microscopy. RESULTS: Parenchymal damage of both parotid and submandibular glands, specially acinar structures comprising cell organelles and nuclei, of animals pretreated with amifostine was much less pronounced than in animals without amifostine pretreatment. CONCLUSION: The results indicate that parenchymal damage in salivary glands induced by high-dose radioiodine therapy can significantly be reduced by amifostine. Therefore, amifostine therapy may increase quality of life in patients with differentiated thyroid cancer after radioiodine treatment.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号